Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Current Leases (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Current Leases for 7 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases rose 9.97% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.4 million, a 9.97% increase, with the full-year FY2025 number at $2.4 million, up 9.97% from a year prior.
  • Current Leases was $2.4 million for Q4 2025 at Fulcrum Therapeutics, up from $2.3 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.7 million in Q1 2023 to a low of $469000.0 in Q1 2021.
  • A 5-year average of $2.0 million and a median of $2.3 million in 2025 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: skyrocketed 1463.33% in 2021, then dropped 23.7% in 2024.
  • Fulcrum Therapeutics' Current Leases stood at $469000.0 in 2021, then skyrocketed by 454.8% to $2.6 million in 2022, then decreased by 15.76% to $2.2 million in 2023, then fell by 0.27% to $2.2 million in 2024, then rose by 9.97% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Current Leases are $2.4 million (Q4 2025), $2.3 million (Q3 2025), and $2.3 million (Q2 2025).